Literature DB >> 32350027

Bioavailability Based on the Gut Microbiota: a New Perspective.

Feng Zhang1, Fang He2, Li Li2, Lichun Guo2, Bin Zhang2, Shuhuai Yu2, Wei Zhao3.   

Abstract

The substantial discrepancy between the strong effects of functional foods and various drugs, especially traditional Chinese medicines (TCMs), and the poor bioavailability of these substances remains a perplexing problem. Understanding the gut microbiota, which acts as an effective bioreactor in the human intestinal tract, provides an opportunity for the redefinition of bioavailability. Here, we discuss four different pathways associated with the role of the gut microbiota in the transformation of parent compounds to beneficial or detrimental small molecules, which can enter the body's circulatory system and be available to target cells, tissues, and organs. We further describe and propose effective strategies for improving bioavailability and alleviating side effects with the help of the gut microbiota. This review also broadens our perspectives for the discovery of new medicinal components.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  bioavailability; gut microbiota; host metabolism; nutrient and drug outcomes; short-chain fatty acid

Mesh:

Substances:

Year:  2020        PMID: 32350027      PMCID: PMC7194497          DOI: 10.1128/MMBR.00072-19

Source DB:  PubMed          Journal:  Microbiol Mol Biol Rev        ISSN: 1092-2172            Impact factor:   11.056


  150 in total

Review 1.  Factors influencing the measurement of bioavailability, taking calcium as a model.

Authors:  R P Heaney
Journal:  J Nutr       Date:  2001-04       Impact factor: 4.798

Review 2.  Clinical practice. Antibiotic-associated diarrhea.

Authors:  John G Bartlett
Journal:  N Engl J Med       Date:  2002-01-31       Impact factor: 91.245

Review 3.  The gastrointestinal microbiota as a site for the biotransformation of drugs.

Authors:  Tiago Sousa; Ronnie Paterson; Vanessa Moore; Anders Carlsson; Bertil Abrahamsson; Abdul W Basit
Journal:  Int J Pharm       Date:  2008-07-16       Impact factor: 5.875

4.  Separating host and microbiome contributions to drug pharmacokinetics and toxicity.

Authors:  Michael Zimmermann; Maria Zimmermann-Kogadeeva; Rebekka Wegmann; Andrew L Goodman
Journal:  Science       Date:  2019-02-07       Impact factor: 47.728

Review 5.  Anti-obesogenic and antidiabetic effects of plants and mushrooms.

Authors:  Jan Martel; David M Ojcius; Chih-Jung Chang; Chuan-Sheng Lin; Chia-Chen Lu; Yun-Fei Ko; Shun-Fu Tseng; Hsin-Chih Lai; John D Young
Journal:  Nat Rev Endocrinol       Date:  2016-09-16       Impact factor: 43.330

6.  Metabolism of digoxin and absorption site.

Authors:  J O Magnusson; B Bergdahl; C Bogentoft; U E Jonsson
Journal:  Br J Clin Pharmacol       Date:  1982-08       Impact factor: 4.335

7.  Isolation and characterization of three fungi with the potential of transforming glycyrrhizin.

Authors:  Chao Wang; Xiao-Xiao Guo; Xiao-Yan Wang; Feng Qi; Shi-Jiang Feng; Chun Li; Xiao-Hong Zhou
Journal:  World J Microbiol Biotechnol       Date:  2012-12-18       Impact factor: 3.312

8.  Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study.

Authors:  S P Messier; S Mihalko; R F Loeser; C Legault; J Jolla; J Pfruender; B Prosser; A Adrian; J D Williamson
Journal:  Osteoarthritis Cartilage       Date:  2007-06-11       Impact factor: 6.576

Review 9.  Curcumin and cancer: an "old-age" disease with an "age-old" solution.

Authors:  Preetha Anand; Chitra Sundaram; Sonia Jhurani; Ajaikumar B Kunnumakkara; Bharat B Aggarwal
Journal:  Cancer Lett       Date:  2008-05-06       Impact factor: 8.679

10.  Polygonatum odoratum Polysaccharides Modulate Gut Microbiota and Mitigate Experimentally Induced Obesity in Rats.

Authors:  Yan Wang; Yanquan Fei; Lirui Liu; Yunhua Xiao; Yilin Pang; Jinhe Kang; Zheng Wang
Journal:  Int J Mol Sci       Date:  2018-11-13       Impact factor: 5.923

View more
  8 in total

1.  Integration of Gut Microbiota and Metabolomics for Chinese Medicine Research: Opportunities and Challenges.

Authors:  Wu-Wen Feng; Juan Liu; Hao Cheng; Cheng Peng
Journal:  Chin J Integr Med       Date:  2021-11-10       Impact factor: 2.626

2.  Alterations in the Gut Microbiota and Hepatitis-B-Virus Infection in Southern Chinese Patients With Coexisting Non-Alcoholic Fatty Liver Disease and Type-2 Diabetes Mellitus.

Authors:  Weijia Han; Chunyang Huang; Yali Ji; Ling Zhou; Jinjun Chen; Jinlin Hou
Journal:  Front Med (Lausanne)       Date:  2021-12-21

Review 3.  Pharmacokinetic, Metabolism, and Metabolomic Strategies Provide Deep Insight Into the Underlying Mechanism of Ginkgo biloba Flavonoids in the Treatment of Cardiovascular Disease.

Authors:  Yi Tao; Fei Zhu; Meiling Pan; Qing Liu; Ping Wang
Journal:  Front Nutr       Date:  2022-03-23

4.  Positive Interventional Effect of Engineered Butyrate-Producing Bacteria on Metabolic Disorders and Intestinal Flora Disruption in Obese Mice.

Authors:  Lina Wang; Xiaoming Cheng; Liang Bai; Mengxue Gao; Guangbo Kang; Xiaocang Cao; He Huang
Journal:  Microbiol Spectr       Date:  2022-03-16

5.  Study on the Antipyretic and Anti-inflammatory Mechanism of Shuanghuanglian Oral Liquid Based on Gut Microbiota-Host Metabolism.

Authors:  Yan Gao; Lu Liu; Chen Li; Yu-Ting Liang; Jing Lv; Long-Fei Yang; Bo-Nian Zhao
Journal:  Front Pharmacol       Date:  2022-06-28       Impact factor: 5.988

Review 6.  Microbiota and COVID-19: Long-term and complex influencing factors.

Authors:  Jiaqi Gang; Haiyu Wang; Xiangsheng Xue; Shu Zhang
Journal:  Front Microbiol       Date:  2022-08-12       Impact factor: 6.064

Review 7.  Dietary compounds in modulation of gut microbiota-derived metabolites.

Authors:  Wuwen Feng; Juan Liu; Hao Cheng; Dandan Zhang; Yuzhu Tan; Cheng Peng
Journal:  Front Nutr       Date:  2022-07-19

8.  The interactions between traditional Chinese medicine and gut microbiota: Global research status and trends.

Authors:  Shanshan Yang; Shaodong Hao; Qin Wang; Yanni Lou; Liqun Jia; Dongmei Chen
Journal:  Front Cell Infect Microbiol       Date:  2022-09-12       Impact factor: 6.073

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.